learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 801 resultslearn Setipiprant
learn GT20029
research compound made to degrade androgen receptors in scalp
learn 18β-glycyrrhetinic acid
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 158 resultsresearch The GPR30 agonist G-1 promotes hair growth via Wnt/Hedgehog signaling in mice
G-1 promotes hair growth in female mice by activating specific signaling pathways.
research The effects of GPR40 agonists on hair growth are mediated by ANGPTL4
GPR40 agonists help hair growth through the protein ANGPTL4.
research Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists
Formyl-peptide receptor agonists could be new anti-inflammatory drugs.
research Leptin controls hair follicle cycling
Leptin helps start the growth phase of hair.
research GPCRs as key regulators in wound healing
GPCRs are vital for wound healing by affecting cell growth and immune response.
Community Join
5 / 1000+ resultscommunity Setipiprant/PGE2 feedbacks?
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community How is the GT20029 different to pyrilutamide as an androgenic antagonist
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Allergan recruiting for Setipiprant trial in the US
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.